Payment overview · 2025
General Payments
$1,442.38
74 reported records · 20 companies
Healthcare provider profile · identity verified
George William Robertson, MD
Allopathic & Osteopathic Physicians|Pediatrics · LEBANON, TN · NPI 1144288747
Verified facts
What the public records show
CMS Open Payments records show George William Robertson, MD received $1,442.38 in general payments during 2025 across 74 reported records.
GlaxoSmithKline, LLC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Edarbi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $226.62 | 15.7% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.89 | 11.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.16 | 9.9% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $134.82 | 9.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.09 | 7.4% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.93 | 7.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.22 | 6.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.87 | 5.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.60 | 4.6% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $61.74 | 4.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.62 | 4.1% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $47.24 | 3.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.88 | 2.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.94 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.90 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.64 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.85 | 1.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.97 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.02 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.38 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,442.38 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $203.46 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $142.16 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $142.16 | 12 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $106.93 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $106.47 | 4 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $106.47 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.22 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.19 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.41 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $75.04 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.87 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.60 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $61.74 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.45 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $52.70 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $47.24 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $45.37 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.46 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.68 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $7.15 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 154 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 28 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
154 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 948 | 294 |
| Levothyroxine Sodium | Levothyroxine Sodium | 644 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 149 |
| Lisinopril | Lisinopril | 456 | 141 |
| Losartan Potassium | Losartan Potassium | 455 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 123 |
| Furosemide | Furosemide | 428 | 112 |
| Omeprazole | Omeprazole | 424 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 420 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 303 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 281 | 74 |
| Trazodone Hcl | Trazodone Hcl | 278 | 78 |
| Sertraline Hcl | Sertraline Hcl | 263 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 254 | 60 |
| Potassium Chloride | Potassium Chloride | 238 | 75 |
| Eliquis | Apixaban | 232 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 225 | 65 |
| Mirtazapine | Mirtazapine | 212 | 48 |
| Allopurinol | Allopurinol | 194 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 77 |
| Carvedilol | Carvedilol | 191 | 48 |
| Gabapentin | Gabapentin | 183 | 66 |
| Simvastatin | Simvastatin | 183 | 52 |
| Prednisone | Prednisone | 179 | 121 |
| Metformin Hcl | Metformin Hcl | 178 | 55 |
| Irbesartan | Irbesartan | 172 | 62 |
| Meloxicam | Meloxicam | 166 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 32 |
| Ozempic | Semaglutide | 154 | 40 |
| Glipizide | Glipizide | 148 | 28 |
| Spironolactone | Spironolactone | 147 | 37 |
| Montelukast Sodium | Montelukast Sodium | 144 | 50 |
| Divalproex Sodium | Divalproex Sodium | 136 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 34 |
| Nifedipine Er | Nifedipine | 136 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 49 |
| Donepezil Hcl | Donepezil Hcl | 124 | 27 |
| Famotidine | Famotidine | 123 | 41 |
| Ezetimibe | Ezetimibe | 120 | 46 |
| Glimepiride | Glimepiride | 119 | 41 |
| Buspirone Hcl | Buspirone Hcl | 116 | 29 |
| Pregabalin | Pregabalin | 115 | 31 |
| Jardiance | Empagliflozin | 111 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 28 |
| Finasteride | Finasteride | 106 | 24 |
| Atenolol | Atenolol | 100 | 34 |
| Baclofen | Baclofen | 93 | 35 |
| Sucralfate | Sucralfate | 83 | 19 |
| Xarelto | Rivaroxaban | 81 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 26 |
| Memantine Hcl | Memantine Hcl | 78 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 25 |
| Januvia | Sitagliptin Phosphate | 74 | 17 |
| Bupropion Xl | Bupropion Hcl | 71 | 23 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 33 |
| Alprazolam | Alprazolam | 67 | 22 |
| Cefdinir | Cefdinir | 67 | 60 |
| Risperidone | Risperidone | 66 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 37 |
| Tramadol Hcl | Tramadol Hcl | 64 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 15 |
| Olanzapine | Olanzapine | 61 | suppressed |
| Azithromycin | Azithromycin | 60 | 54 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 51 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 59 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 44 |
| Synthroid | Levothyroxine Sodium | 58 | 21 |
| Celecoxib | Celecoxib | 57 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 25 |
| Metformin Hcl Er | Metformin Hcl | 54 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 48 | suppressed |
| Levetiracetam | Levetiracetam | 48 | 13 |
| Lidocaine Hcl | Lidocaine Hcl | 48 | 33 |
| Topiramate | Topiramate | 48 | suppressed |
| Ketoconazole | Ketoconazole | 46 | 27 |
| Lorazepam | Lorazepam | 46 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 18 |
| Lovastatin | Lovastatin | 42 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 40 | 31 |
| Cephalexin | Cephalexin | 40 | 23 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 15 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 37 | 19 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | 11 |
| Metolazone | Metolazone | 36 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 16 |
| Valsartan | Valsartan | 36 | 11 |
| Gemtesa | Vibegron | 34 | suppressed |
| Kerendia | Finerenone | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 30 | 24 |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 21 |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Admelog | Insulin Lispro | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 20 |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Rifampin | Rifampin | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Calcitriol | Calcitriol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Nystop | Nystatin | 14 | 11 |
| Rybelsus | Semaglutide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,442.38 · 74 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, EDARBI, ELIQUIS, FANAPT, FARXIGA, Fluad, Flucelvax, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, TRUMENBA, TZIELD, UBRELVY, Veozah, Wegovy, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error